# MSInsight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/msinsight

- Industry: Software
- Headquarters: Boulogne-Billancourt, France
- Website: www.msinsight.tech
- Total disclosed funding: $0.6M
- Latest round: Seed (Jan 7, 2025)
- Investors on record: 5

## About

MSInsight is a biotechnology firm focused on precision oncology, offering advanced diagnostic solutions to enhance cancer treatment outcomes through innovative genomic insights.Founded in 2022, MSInsight operates from Boulogne-Billancourt, France, specializing in precision oncology. The company has completed one significant deal to date. The founder has not been disclosed, nor is there information about prior ventures. MSInsight recently raised EUR 1.6 million in Seed funding on March 10, 2025, from investors including Bpifrance Investissement, Calyseed, Capital Cell Investors, France Angels, and Yes Securities.MSInsight specializes in precision oncology through its flagship product, MSIcare, which utilizes next-generation sequencing (NGS) technology to detect microsatellite instability (MSI) in both solid tumors and liquid biopsies. This diagnostic tool addresses a critical need for accurate identification of MSI, a significant biomarker linked to DNA repair system dysfunction, which plays a crucial role in determining patient eligibility for specific immunotherapies. Launched in 2022, MSIcare empowers healthcare providers by offering detailed genomic insights, enabling them to tailor treatment plans that enhance patient outcomes. The company serves a diverse range of clients including hospitals, oncology clinics, and research institutions, primarily in Europe and North America, where there is a growing demand for advanced cancer diagnostics and personalized treatment strategies.The revenue model for MSInsight is based primarily on the provision of diagnostic services through its proprietary software, MSIcare. The company engages in B2B transactions with healthcare providers who integrate its diagnostic capabilities into their clinical workflows. Clients typically pay for MSI analysis services, which may include one-time fees for individual patient assessments or subscription models for ongoing access to the software and data analysis tools. These transactions facilitate comprehensive reporting on MSI status, aiding in the personalized treatment planning process for cancer patients. Revenue is generated from diagnostic services, reflecting the increasing reliance on genomic data to inform therapeutic decisions in oncology.In March 2025, MSInsight raised EUR 1.6 million in Seed funding to finalize its technological development, demonstrate its performance in various cancers, and initiate regulatory clinical validation for its CE-IVD marking as an in vitro diagnostic medical device. The company plans to expand its product line with enhancements to MSIcare and aims to penetrate new markets in Asia and North America by late 2025.

## Funding rounds

- Seed, Jan 7, 2025, $0.6M — Bpifrance Investissement, Yes Securities, France Angels, Capital Cell Investors, Calyseed

## Investors

- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Seed
- Yes Securities — Seed
- France Angels — Seed
- Capital Cell Investors — Seed
- Calyseed — Seed